{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:55:45Z","timestamp":1793350545016,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010805","name":"Forskningsr\u00e5det i Syd\u00f6stra Sverige","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003461","name":"Gunnar Nilssons Cancerstiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejca.2018.12.034","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T19:08:37Z","timestamp":1549998517000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effects of adjuvant tamoxifen over three decades on breast cancer\u2013free and distant recurrence\u2013free interval among premenopausal women with oestrogen receptor\u2013positive breast cancer randomised in the Swedish SBII:2pre trial"],"prefix":"10.1016","volume":"110","author":[{"given":"M.","family":"Ekholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.O.","family":"Bendahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fern\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nordenskj\u00f6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"St\u00e5l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.12.034_bib1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.034_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"suppl; abstr 5","key":"10.1016\/j.ejca.2018.12.034_bib3","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib4","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.2015.65.6272","article-title":"Two years of adjuvant tamoxifen provides a survival benefit compared with No systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (> 25 years) of the phase III SBII:2pre trial","volume":"34","author":"Ekholm","year":"2016","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2004.06.030","article-title":"Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up","volume":"41","author":"Ryden","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.12.034_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"(EBCTCG) EBCTCG","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.12.034_bib7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/88.21.1543","article-title":"Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer","volume":"88","author":"Rutqvist","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2018.12.034_bib8","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3109\/0284186X.2015.1037012","article-title":"Highly reproducible results of breast cancer\u00a0biomarkers when analysed in accordance with national guidelines \u2013 a Swedish survey with central re-assessment","volume":"54","author":"Ekholm","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","article-title":"Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers","volume":"123","author":"Nadji","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2018.12.034_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/annonc\/mdv106","article-title":"Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)","volume":"26","author":"Gourgou-Bourgade","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib11","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1093\/annonc\/mdv478","article-title":"Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)","volume":"26","author":"Gourgou-Bourgade","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib13","series-title":"Analysing survival data from clinical trials and observational studies","first-page":"335","author":"Marubini","year":"1995"},{"key":"10.1016\/j.ejca.2018.12.034_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1536867X0400400201","article-title":"Cumulative incidence estimation in the presence of competing risks","volume":"4","author":"Coviello","year":"2004","journal-title":"STATA J"},{"key":"10.1016\/j.ejca.2018.12.034_bib15","first-page":"348","article-title":"Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer - own findings and review of the literature","volume":"36","author":"Kleeberg","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2018.12.034_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1634\/theoncologist.2014-0273","article-title":"Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon","volume":"20","author":"Fink","year":"2015","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib17","first-page":"4399","article-title":"Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project","volume":"41","author":"Chlebowski","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.12.034_bib18","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1998.16.7.2401","article-title":"Construction and validation of a practical prognostic index for patients with metastatic breast cancer","volume":"16","author":"Yamamoto","year":"1998","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.034_bib19","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/1097-0142(20001201)89:11<2169::AID-CNCR4>3.0.CO;2-9","article-title":"Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy","volume":"89","author":"Lluch","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2018.12.034_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/A:1010616532332","article-title":"Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer","volume":"66","author":"Alba","year":"2001","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2018.12.034_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00280-009-1141-3","article-title":"Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge","volume":"66","author":"Vauleon","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2018.12.034_bib22","first-page":"685","article-title":"Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen","volume":"71","author":"Fornander","year":"1987","journal-title":"Cancer Treat Rep"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:34:41Z","timestamp":1762342481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919300127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":22,"alternative-id":["S0959804919300127"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of adjuvant tamoxifen over three decades on breast cancer\u2013free and distant recurrence\u2013free interval among premenopausal women with oestrogen receptor\u2013positive breast cancer randomised in the Swedish SBII:2pre trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}